Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
companyunderground
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
Companies
» Company Monitoring Page for Eisai
Company Monitoring Page for Eisai
latest headlines for company on cafepharma
Biogen, Eisai face down another Aduhelm refusal—this time from Japanese regulators
Fierce Pharma
Wed, 12/22/21 - 11:06 am
Tags:
Biogen
,
Eisai
,
Aduhelm
,
Japan
,
Alzheimer's disease
Licensing deals rack up in 2021
EP Vantage
Fri, 12/10/21 - 10:46 am
Tags:
licensing
,
GSK
,
Alector
,
Novartis
,
BeiGene
,
Pfizer
,
Arvinas
,
iTeos Therapeutics
,
Bristol Myers Squibb
,
Eisai
Eisai-Biogen Alzheimer's Drug Shows Amyloid Reduction, Disease-Modifying Effect
BioSpace
Thu, 11/11/21 - 10:55 am
Tags:
Eisai
,
Biogen
,
lecanemab
,
Alzheimer's disease
,
clinical trials
What Novartis could buy with its windfall
EP Vantage
Fri, 11/5/21 - 09:40 am
Tags:
Novartis
,
M&A
,
Roche
,
Sandoz
,
Aurinia Pharmaceuticals
,
Alnylam
,
Exelixis
,
Incyte
,
Eisai
,
Genmab
Eisai-backed trial will assess Altoida’s digital test for early Alzheimer’s
Pharmaforum
Wed, 10/20/21 - 10:08 am
Tags:
Altoida
,
Eisai
,
clinical trials
,
augmented reality
,
Alzheimer's disease
Seizing Aduhelm precedent, Biogen, Eisai get the ball rolling on another accelerated Alzheimer's approval
Endpoints
Tue, 09/28/21 - 12:07 am
Tags:
Biogen
,
Aduhelm
,
Eisai
,
Alzheimer's disease
,
FDA
,
lecanemab
FDA Action Alert: Cara/Vifor, Kadmon, BMS, Merck/Eisai
BioSpace
Mon, 08/23/21 - 11:10 am
Tags:
FDA
,
Cara Therapeutics
,
Vifor Pharma
,
Korsuva
,
Kadmon
,
belumosudil
,
Bristol Myers Squibb
,
Opdivo
,
Merck
,
Eisai
,
Keytruda
Merck's Best Seller Keytruda Racks Up Another Regulatory Win
BioSpace
Thu, 08/12/21 - 12:35 pm
Tags:
Merck
,
Keytruda
,
advanced renal cell carcinoma
,
renal cell carcinoma
,
Eisai
,
Lemvima
,
FDA
Biogen, Eisai are pushing for another accelerated Alzheimer's OK — this time for BAN2401
Endpoints
Wed, 08/4/21 - 10:55 am
Tags:
Biogen
,
Eisai
,
FDA
,
Alzheimer's disease
,
BAN2401
Biogen Partner Pushing On With Alzheimer’s Drug Despite Fracas
Bloomberg
Thu, 07/15/21 - 10:45 am
Tags:
Biogen
,
Eisai
,
Alzheimer's disease
,
lecanemab
,
BAN2401
Eisai-Biogen Alzheimer’s drug gets FDA breakthrough designation
Pharmaceutical Business Review
Thu, 06/24/21 - 10:56 am
Tags:
Eisai
,
Biogen
,
FDA
,
lecanemab
,
breakthrough status
,
Alzheimer's disease
Bristol Myers pays $650M for rights to Eisai's phase 1 ADC
Fierce Biotech
Fri, 06/18/21 - 10:11 am
Tags:
Bristol Myers Squibb
,
antibody-drug conjugate
,
MORAb-202
,
Eisai
Bristol-Myers, Eisai in up to $3.1 bln deal to develop cancer drug candidate
Reuters
Thu, 06/17/21 - 10:56 pm
Tags:
Bristol Myers Squibb
,
Eisai
,
drug development
,
cancer
When Will Lecanemab be Available to Alzheimer’s Patients?
BioSpace
Tue, 04/20/21 - 11:11 pm
Tags:
Eisai
,
lecanemab
,
BAN2401
,
Alzheimer's disease
Biogen's Aducanumab: A Look at the Drug’s History and Recent Updates
BioSpace
Sat, 03/27/21 - 12:14 pm
Tags:
Biogen
,
Eisai
,
aducanumab
,
Alzheimer's disease
Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer
Endpoints
Fri, 03/19/21 - 10:51 am
Tags:
Merck
,
FDA
,
Keytruda
,
Eisai
,
Lenvima
,
clinical trials
,
endometrial cancer
Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021
PR Newswire
Tue, 03/9/21 - 10:45 am
Tags:
Clarivate
,
Biogen
,
Eisai
,
aducanumab
,
UCB Pharma
,
bimekizumab
,
Relugolix
,
Pfizer
,
Takeda
,
Myovant
,
vericiguat
,
Bayer
,
Merck
Merck's Keytruda Plus Eisai's Lenvima Could Open New Standard of Care in Renal Cancer
BioSpace
Tue, 02/16/21 - 11:12 am
Tags:
Merck
,
ASCO GU
,
Keytruda
,
Eisai
,
Lenvima
,
renal cell carcinoma
FDA extends review period for Biogen's Alzheimer's drug
Reuters
Fri, 01/29/21 - 10:06 am
Tags:
Biogen
,
Eisai
,
FDA
,
aducanumab
,
Alzheimer's disease
Aducanumab tops 2021’s biggest potential launches
EP Vantage
Mon, 01/18/21 - 01:04 pm
Tags:
drug launches
,
Biogen
,
Eisai
,
aducanumab
,
efgartigimod
,
Argenx
,
Evrenzo
,
FibroGen
,
Astellas
,
AstraZeneca
,
Leqvio
,
Novartis
,
UCB Pharma
,
bimekizumab
,
Ascendis Pharma
,
Bluebird Bio
,
Bristol-Myers Squibb
,
ide-cel
,
liso-cel
,
AXS-05
,
Axsome Therapeutics
,
voclosporin
,
Aurinia
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »
last 30 twitter posts
current feelings about your job
job rating
*
1 - I hate my job
2
3
4
5
6
7 - I love my job
Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
please tell us why
*
your industry
*
your job title (optional)
your company
*
published
N/A
published
not published
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
cafepharma is a: rock, tree, site
*
Fill in the blank.